• Xipeng Liu, Ming Liu, Bing Cao, Jianxin Qiao, and Xiufeng Zhang.
• Xiping Liu, Department of Neurosurgery, The First Affiliated Hospital of Hebei North University Zhangjiakou 075000, Hebei Province, P.R. China.
• Pak J Med Sci. 2023 May 1; 39 (3): 843847843-847.

ObjectiveTo investigate the relationship between isocitrate dehydrogenase (IDH) 1/2 mutation, telomerase reverse transcriptase (TERT) gene promoter mutation and the prognosis of human glioma patients.MethodsOne hundred fifteen patients with human glioma, treated surgically in The First Affiliated Hospital of Hebei North University from January 2019 to January 2020, were included. All patients were followed up until January 31, 2022. The mutations of IDH1/2 and TERT promoter were analyzed, and risk factors affecting survival of the patients with glioma were assessed.ResultsIDH1 gene mutation occurred in 82 cases, IDH2 gene mutation occurred in five cases and TERT promoter mutation occurred in 54 cases. Univariate analysis showed that tumor WHO grade, resection range, preoperative Karnofsky performance status score, postoperative radiotherapy and chemotherapy, IDH1/2 gene and TERT promoter mutation influenced postoperative survival of patients with glioma (P<0.05). Kaplan-Meier survival curve showed that IDH1/2 gene and TERT promoter mutation were significantly different from those of wild-type patients (P<0.05).ConclusionIDH1/2 gene and TERT promoter mutations are more frequent in patients with human glioma. These related factors can be used as molecular markers to aid in the prognosis of patients with glioma.Copyright: © Pakistan Journal of Medical Sciences.

4 keywords...

hide…